Mineralys Therapeutics MLYS 深 沪
已收盘 07-02 16:00:00 美东时间
27.69
+0.800
+2.98%
华盛通- 最 高27.77
- 今 开27.20
- 成交量 70.08万股
- 最 低 26.76
- 昨 收 26.89
- 总市值 24.41亿
- 52周最高 47.65
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 12.59
- 委 比 1.96%
- 总股本 8815.85万
- 历史最高 47.65
- 量 比 0.31
- 振 幅 3.76%
- 历史最低 5.85
- 每 手 1
- 风险率 9.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mineralys says lorundrostat reduces heart failure risk biomarkers in post hoc analysis of hypertension trials
Mineralys says lorundrostat reduces heart failure risk biomarkers in post hoc analysis of hypertension trials Mineralys Therapeutics presented late-breaking ENDO 2026 data from a post hoc proteomic analysis of lorundrostat in uncontrolled hypertension. The analysis showed reductions in several bioma
06-14 22:00
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics presented new data showing that lorundrostat significantly reduced heart failure risk biomarkers in participants with uncontrolled hypertension. The analysis, from the Launch-HTN and Advance-HTN trials, demonstrated coordinated reductions in fibrosis and heart failure biomarkers, suggesting potential modulation of disease pathways. Lorundrostat also increased renin and decreased angiotensinogen, reflecting RAAS engagement. ...
06-14 14:00
Mineralys announces $150 million equity offering and financing
An update from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On Ju...
06-04 04:50
Mineralys Therapeutics prices $150M stock offering
Mineralys Therapeutics (MLYS) has priced an offering of 5.66M shares of its common stock at a price of $26.50 per share. The gross proceeds from the offering are expected to be around $150M. Mineralys...
06-03 18:31
Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)
06-03 18:08
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics announced the pricing of an underwritten offering of 5,660,378 shares of its common stock at $26.50 per share, expected to raise approximately $150 million in gross proceeds. The offering is set to close on June 4, 2026, subject to customary conditions. Proceeds will be used to partially fund a $200 million upfront payment for repurchasing a royalty obligation under its license agreement with Tanabe Pharma Corporation. BofA...
06-03 10:05
Mineralys publishes ESH 2026 presentation on lorundrostat in CKD hypertension trial
Mineralys publishes ESH 2026 presentation on lorundrostat in CKD hypertension trial Mineralys published an ESH 2026 presentation on lorundrostat for hypertension in chronic kidney disease, reporting results from the LAUNCH-HTN trial. Primary endpoint: ambulatory office systolic blood pressure fell 1
06-01 22:35
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
Mineralys Therapeutics, a biopharmaceutical company targeting hypertension and related diseases, announced that its management will participate in the Jefferies 2026 Global Healthcare Conference in New York on June 2-4, 2026. A corporate presentation will be held on June 3, 2026, at 7:35am EDT, with a live webcast available on the company's website. Mineralys focuses on developing medicines for conditions like chronic kidney disease and obstructi...
05-27 12:00
Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –
05-19 04:10
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breast cancer treatment.
05-19 00:59
